Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: jackie who wrote (7175)	9/4/1998 11:01:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

You want more Jack? Hot off the press. read em and weep.>>>>>>> >>>>http://www.univie.ac.at/ESS/newpap/sept98.htm Read the editorial, and check out Dr Opals comments AND credendtials.

To: jackie who wrote (7175)	9/4/1998 11:03:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Jack, I missed this from the XOMA site. Late Sept meeting ICAAC in San Diego. September '98 International Endotoxin Society Meeting 12, Santa Fe, NM Pat Scannon, M.D., Ph.D., rBPI-21 Clinical Update 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC '98), ASM's Annual Meeting on Infectious Diseases 24-27, San Diego, CA Steve Carroll, Ph.D., "Plasma Levels of Lipopolysaccharide Binding Protein (LBP) Indicate That Hemorrhagic Trauma Patients, Partial Hepatectomy Patients and Cystic Fibrosis Patients Have Been Systemically Exposed to Bacteria and Endotoxin" Peter Heseltine, M.D., "Open-label, Pilot Phase II Trial of Three Dose Levels of Recombinant Bactericidal/ Permeability- Increasing Protein (rBPI-21) Administered by Continuous Intravenous Infusion to Patients with Complicated Intra-Abdominal Infections" Arnold Horwitz, Ph.D., "rBPI(10-193) is Secreted by CHO Cells and Retains the Activity of rBPI-21" Lewis Lambert, M.S., "Recombinant Bactericidal/ Permeability- Increasing Protein in Combination with Sulfadiazine is Remarkably Active Against Toxoplasma gondii" Roger Little, Ph.D., "XMP Antifungal Peptides Demonstrate Enhanced Selectivity and Oral Availability"